ArticleProstate cancer and prostatic diseases2012
ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer--a comparative study of two monoclonal antibodies.
Article in Prostate cancer and prostatic diseases, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 79 citations in OpenAlex.
- The prognostic significance of combined ERG and androgen receptor expression in patients with prostate cancer managed by androgen deprivation therapy.Cancer biology & therapy · 2014Trial
- EpCAM tumor specificity and proteoform patterns in urothelial cancer.Journal of cancer research and clinical oncology · 2023Article
- TRIM21 Expression as a Prognostic Biomarker for Progression-Free Survival in HNSCC.International journal of molecular sciences · 2023Article
- TRIM24 Expression as an Independent Biomarker for Prognosis and Tumor Recurrence in HNSCC.Journal of personalized medicine · 2022Article
- Comparison of manual and automated digital image analysis systems for quantification of cellular protein expression.Histology and histopathology · 2022Article
- Article
- Recent Advances in Nanomedicine for the Diagnosis and Treatment of Prostate Cancer Bone Metastasis.Molecules (Basel, Switzerland) · 2021Review
- Spatial Distribution of Immune Cells in Head and Neck Squamous Cell Carcinomas.Frontiers in oncology · 2021Article
- NR2F6 as a Prognostic Biomarker in HNSCC.International journal of molecular sciences · 2020Article
- CDK19 as a Potential HPV-Independent Biomarker for Recurrent Disease in HNSCC.International journal of molecular sciences · 2020Article
- EVI1 as a Marker for Lymph Node Metastasis in HNSCC.International journal of molecular sciences · 2020Article
- ERG Tumor Type is Less Frequent in High Grade and High Stage Prostate Cancers of Chinese Men.Journal of Cancer · 2019Article
- Ethnicity and ERG frequency in prostate cancer.Nature reviews. Urology · 2018Review
- Article
- Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis.International journal of molecular sciences · 2017Article
- Expression of ERG Protein and TMRPSS2-ERG Fusion in Prostatic Carcinoma in Egyptian Patients.Open access Macedonian journal of medical sciences · 2017Article
- SPINK1 Overexpression in Localized Prostate Cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous PTEN Deletion.Pathology oncology research : POR · 2017Article
- Article
- miRNAs as drivers of TMPRSS2-ERG negative prostate tumors in African American men.Frontiers in bioscience (Landmark edition) · 2017Review
- Prognostic value of ERG, PTEN, CRISP3 and SPINK1 in predicting biochemical recurrence in prostate cancer.Oncology letters · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOverexpression of the ERG protein is highly prevalent in prostate cancer (PCa) and commonly results from gene fusions involving the ERG gene. Recently, N-terminal epitope-targeted mouse and a C-terminal epitope-targeted rabbit monoclonal anti-ERG antibody (ERG-MAbs) have been introduced for the detection of the ERG protein. Independent studies reported that immunohistochemistry (IHC) with both ERG-MAbs highly correlates with the underlying ERG gene rearrangement status. However, comparative studies of both antibodies are lacking. Here, we are among the first to compare the mouse ERG-MAb with the rabbit ERG-MAb for their concordance on the same PCa cohort. Furthermore, we assessed whether the ERG protein expression is conserved in lymph node and distant PCa metastases.
methodsWe evaluated tissue microarrays of 278 specimens containing 265 localized PCa, 29 lymph node, 30 distant metastases and 13 normal prostatic tissues. We correlated ERG protein expression with ERG rearrangement status using an ERG break-apart fluorescence in-situ hybridization assay and IHC of both ERG-MAbs.
resultsERG expression and ERG rearrangement status were highly concordant regardless of whether the mouse or rabbit ERG-MAb was used (97.8% versus 98.6%, respectively). Of interest, both ERG antibodies reliably detected the ERG expression in lymph node and distant PCa metastases, of which a subset underwent decalcification. Lymphocytes only revealed immunoreactivity using the rabbit ERG-MAb. If ERG protein expression was present in localized PCa, we observed the same pattern in the corresponding lymph node metastases.
conclusionsBy demonstrating a broad applicability of IHC to study ERG protein expression using either antibody, this study adds an important step toward a facilitated routine clinical application. Further, we demonstrate that the clonal nature of the ERG rearrangement is not restricted to the genomic level, but proceeds in the proteome. Together, our results simplify future efforts to further eliucidate the biological role of ERG in PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.